All GLG News Analyses Filed Under: Ophthalmology

Promising Eye Drop for Dry Age-Related Macular Degeneration.

April 15, 2009

Analysis by: GLG Expert Contributor

Analysis of:Eye drop treatment for dry AMD shows promise in Phase 2 trial | www.othera.com

Othera Pharmaceuticals, Inc. announced positive interim data results from its Phase 2 trial of OT-551 in treating geographic atrophy (GA) in dry AMD. OT-551 is a topically-dosed, patented small molecule that acts on oxidative stress and disease-induced inflammation. The 12-month findings from the two-year trial suggest an emerging trend for reducing moderate vision loss in 137 patients with GA who were treated with OT-551 compared with placebo.

Traby or AA for uncontrolled IOP

April 6, 2009

Analysis by: GLG Expert Contributor

Analysis of:Arch Ophthalmol -- Abstract: Reduction of Intraocular Pressure With Anecortave Acetate in Eyes With Ocular Steroid Injection-Related Glaucoma, February 2009, Robin et al. 127 (2): 173 | archopht.ama-assn.org

This  drug  may have a great potential   in lowering IOP Another  Alternative  or an addition in medical management  of  raised IOP might save surgery in many patients

Steve RubinsteinOptometristSound Shore Vision Care

Laser Vision Correction for Presbyopia is here!

April 6, 2009

Analysis of:Presbyopic laser vision correction reduces spectacle dependence in pseudophakes | www.modernmedicine.com

The missing element in LVC today is real multifocal correction to deal with a the large population of baby boomers that are finding a need for a different correction for distance vision than near vision(most people over 40 years of age). As of now we have only two options for adults: 1) two eyes corrected for distance vision and reading glasses or 2) mono-vision, one eye corrected for near, and the other corrected for distance vision. We currently have the ability to create mulitfocal spectacle lenses, and multifocal contact lenses. Johnson & Johnson's Vistakon just released a new Acuvue for Presbyopia in March 2009, CooperVision and Bausch & Lomb have both had multifocal contact lenses for years.

Alcon's Potential New Glaucoma Treatment: Anecortave Acetate.

April 5, 2009

Analysis by: GLG Expert Contributor

Analysis of:Arch Ophthalmol -- Abstract: Reduction of Intraocular Pressure With Anecortave Acetate in Eyes With Ocular Steroid Injection-Related Glaucoma, February 2009, Robin et al. 127 (2): 173 | archopht.ama-assn.org

Alcon (ACL) is working on an intriguing new treatment modality for glaucoma.  Unlike previous drops that require daily dosing, this medication only needs to be given every three months. This small case series reports promising results where anecortave acetate lowers intraocular pressure in steroid induced ocular hypertension.

Rho Kinase Inibitors could be a New Approach in Glaucoma Management.

April 5, 2009

Analysis by: GLG Expert Contributor

Analysis of:Arch Ophthalmol -- Abstract: Intraocular Pressure-Lowering Effects and Safety of Topical Administration of a Selective ROCK Inhibitor, SNJ-1656, in Healthy Volunteers, March 2008, Tanihara et al. 126 (3): 309 | archopht.ama-assn.org

Rho Kinase Inhibitors could be the next big step in Glaucoma Management.  Rho kinase inhibition has been studied in various animal models to lower intraocular pressure; and this is the first clinical report involving healthy human subjects.  The potential of this class is large in a field where there have not been many developments recently.

Mark PackerClinical Associate Professor of OphthalmologyOREGON HEALTH & SCIENCE UNIVERSITY - CC

Tecnis Multifocal FDA Data Shatters the Bifocal Glasses Ceiling

April 1, 2009

Analysis of:Summary of Safety and Effectiveness Data (FDA) | www.fda.gov

The approval of the Tecnis Multifocal IOL represents an exciting new alternative for patients in the United States with cataracts and those presbyopic individuals who desire spectacle independence.  With the highest level of subjects who never wear glasses ever reported in an FDA monitored investigation, the Tecnis Multifocal heads to the front of the pack of the multifocal, presbyopia correcting IOLs.  The crystalens (B & L, Rochester, NY) remains the only approved accommodative IOL in the United States.

Lens Refilling to Restore Accommodation-Too Good to be True?

March 5, 2009

Analysis by: GLG Expert Contributor

Analysis of:Lens refilling to restore accommodation | www.sciencedirect.com

The article written by Nishi et al. in the Journal of Cataract and Refractive Surgery describes methodology that may (with emphasis on "may") create better methods of using liquid polymers in refilling the crystalline lens capsular bag as a substitute to rigid intraocular lens implants following cataract surgery. The concept is intriguing, but the science is lacking. What differentiates these researchers work from existing, is that they feel they have achieved better technologies that could advance the science. Realizing a liquid replacement for the human lens is an exciting concept. The hurdles that are positioned in translating that concept into a workable prototype are however, still looming large. undefined

Lens Refiilling

March 4, 2009

Analysis by: GLG Expert Contributor

Analysis of:Lens refilling to restore accommodation | www.sciencedirect.com

Once this technology works and matures it will be the de facto procedure for all human beings over the age of 45.  In other words a multi-billion dolar product and procedure.

Cataract Surgery Option Still Falls Short

March 4, 2009

Analysis by: GLG Expert Contributor

Analysis of:Lens refilling to restore accommodation | www.sciencedirect.com

The article on lens refilling to restore accommodations is an option to an ongoing debate.  The debate as to what causes humans to lose accommodation after forty is yet unresolved.  Once a patient develops a cataract that is visually significant the accommodation option is a bonus but the ability to see is what is foremost on their mind.  The current presbyopia "correcting" IOLs are much better than they were four years ago.  They have made more progress than this technology.  Alcon seems to lead the market currently with its newly approved +3 diopter Restor lens.  It corrects from the prior +4 issues that patients were having.  They are overall happier.  This technology of refilling the lens still needs a great deal of work in order to adjust for the power of the lens needed as well as glare, halo and other complaints.  It will not be quickly adopted and optometrist although regulated state to state will not be able to perform this procedure.  It is still intraocular.

The future of lens refilling post cataract extraction

March 3, 2009

Analysis by: GLG Expert Contributor

Analysis of:Lens refilling to restore accommodation | www.sciencedirect.com

Current replacement methods for extracted crystalline lens include accommodative intraocular lens that are enthusiastically being incorporated in current practice.  Refilling the capsular bag is an exciting concept but no successful technique is currently available.

Previous Page : 12345678910Next21 to 30 of 304